Scientific Program - ENDOCRINE TUMORS
Monday, 27th Feb 2006

Time

Topic
Speaker
Chairpersons
8:30 – 9:00 Registration    
9:00 – 9:05 Introduction    
  Pitutary Tumors    
9:10 – 9:25
Imaging modality of choice for diagnosis and defining the extent of pituitary adenomas
Dr.NM Merchant Dr. Rajiv Sarin
9:25-9:40
Timing of postop scan interpretation for assessing residual disease
Dr.S Pungavkar
9:40-10:00
Role of IHC, EM, etc in the diagnosis of pituitary adenomas, subtyping and biological behaviour
Dr.S Kane/
Dr. S Sharma
10:00-10:15 Tea
10:15-10:35
Surgical strategies and approaches for pituitary adenomas
Dr.A. Goel Dr.Rajiv Sarin
10:35-11:00
Timing of RT and newer techniques in pituitary adenoma
Dr.R Jalali Dr Padma Menon
11:00-11:15
Prolactionoma
Dr.P.Vertakavi Dr.Rajiv sarin
11:15-11:30
Acromegaly
Dr.M.Chaddha Dr.Rajiv sarin
11:30-11:45 Cushing’s syndrome Dr.P. Menon  
11:45-12:00 Optimum replacement therapy Dr.N.Shah  
12:00-12:20 Sequelae of treatment Dr.S. Kumar  
12:20-12:50 Discussion
12:50-13:00
Need for dedicated multidisciplinary units and conclusions
Dr.R Jalali,Dr.N Shah,Dr.A Goel,
Dr.R Sarin
13:00 – 14:00 Lunch
  Gastro-intestinal Neuro Endocrine Tumors
14:00 – 14:20
What is role of imaging in detecting functioning but occult NET?
Dr.K. Öberg Dr.P.Jagannath
Dr.S.Mehta
14:20 – 14:40
Is there a role of adjuvant therapy after curative surgery in NET?
Dr.B. Wiedenmann
14:40 – 15:00
What is the role of debulking (partial resection, RFA embolisation etc) in the management of NET?
Dr.P. J. Shukla,
15:00 – 15:20
What is the role of palliative Chemotherapy in the treatment of Metastatic NETs?
Dr.K.M. Mohandas
15:20 – 15:35
Question and answers
 
15:35 – 15:50 Tea
15:50 – 16:10
What is the role of somatostatin analogues in symptomatic and asymptomatic patients with non resectable NETs?
Dr.B.Wiedenmann Dr.V.Dhir
Dr.D.Desai
16:10 – 16:30
When should one screen for familial NET?
Dr.K. Öberg
16:30 – 16:50 Indian Experience Dr.K.M. Mohandas
16:50 – 17:45 Question and Answers  

 

Desgined by Swraj.com